Strong set of numbers, driven by new drugs, primarily Cosentyx and Entresto. Volume gains strong enough to combat generic competition as well as price erosion. Lower price erosion in Q2 vs Q1 marks the sequential out-performance. Sandoz does not offer much hope in the near term, but innovative medicines remain robust.
18 Jul 2018
Solid market-beating numbers
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid market-beating numbers
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
18 Jul 2018 -
Author:
Kamla Singh -
Pages:
3
Strong set of numbers, driven by new drugs, primarily Cosentyx and Entresto. Volume gains strong enough to combat generic competition as well as price erosion. Lower price erosion in Q2 vs Q1 marks the sequential out-performance. Sandoz does not offer much hope in the near term, but innovative medicines remain robust.